Javascript must be enabled to continue!
THE STUDIES ASSESSING STATIN IN CORONARY ATHEROSCLEROSIS PLAQUE PROGRESSION
View through CrossRef
Objectives
to assess the effect of therapy with statins on plaques.
Methods
searched eligible studies on PubMed, Embase databases and analysed them through Review Manager 5. The primary terminal point was the progression of plaque volume evaluated by intravascular ultrasound (IVUS). Weighted mean difference (WMD) was used as summary statistics for the results (continuous variables). Heterogeneity of the studies was analysed by Cochran's Q statistics. Sensitivity of the studies was analysed by stratified analysis according to the time of follow-up, the level of LDL-C and statins. All of biases of the studies were analysed by funnel plot.
Results
This meta-analysis adopted 19 studies from 14 papers. The total number of patients was 2631 and the mean follow-up was 18.7 months. That found a significant regression in coronary atherosclerotic plaque volume (WMD −6.59 mm3, 95% CI (−8.75 to −4.43) p<0.00001), with no significant heterogeneity across studies (p=0.78). Stratified analysis: Time of the follow-up >6 months (WMD −6.75 mm3, 95% CI (−9.10 to −4.40) p<0.00001) presented a trend for plaque regression through the follow-up ≤6 months (WMD −5.74 mm3, 95% CI (−11.20 to −0.28) p=0.04). Treatment with atorvastatin (WMD −6.83 mm3, 95% CI (−11.68, to −1.99) p=0.006) showed a stronger regression than rosuvastatin (WMD −6.41 mm3, 95% CI (−9.43 to −3.40) p<0.0001). At the end of follow-up, the LDL-C level on 80–100 mg/dl (WMD −8.88 mm3, 95% CI (−12.96 to −4.81) p<0.0001) reveal the strongest trend for plaque regression among all of the three LDL levels, including >80 mg/dl (−6.01 mm3, 95% CI (−8.82 to −3.21) p<0.0001), 80–100 mg/dl and <100 mg/dl (WMD −4.22 mm3, 95% CI (−10.27 to 1.82) p=0.017). Plaque volume remained essentially unchanged in patients not treated with statins (WMD 0.13 mm3, 95% CI (−4.42 to 4.68) p=0.96).
Conclusions
statin therapy, particularly when achieving the LDL level on 80–100 mg/dl, appears to promote a significant regression of coronary plaque volume as measured by IVUS.
Title: THE STUDIES ASSESSING STATIN IN CORONARY ATHEROSCLEROSIS PLAQUE PROGRESSION
Description:
Objectives
to assess the effect of therapy with statins on plaques.
Methods
searched eligible studies on PubMed, Embase databases and analysed them through Review Manager 5.
The primary terminal point was the progression of plaque volume evaluated by intravascular ultrasound (IVUS).
Weighted mean difference (WMD) was used as summary statistics for the results (continuous variables).
Heterogeneity of the studies was analysed by Cochran's Q statistics.
Sensitivity of the studies was analysed by stratified analysis according to the time of follow-up, the level of LDL-C and statins.
All of biases of the studies were analysed by funnel plot.
Results
This meta-analysis adopted 19 studies from 14 papers.
The total number of patients was 2631 and the mean follow-up was 18.
7 months.
That found a significant regression in coronary atherosclerotic plaque volume (WMD −6.
59 mm3, 95% CI (−8.
75 to −4.
43) p<0.
00001), with no significant heterogeneity across studies (p=0.
78).
Stratified analysis: Time of the follow-up >6 months (WMD −6.
75 mm3, 95% CI (−9.
10 to −4.
40) p<0.
00001) presented a trend for plaque regression through the follow-up ≤6 months (WMD −5.
74 mm3, 95% CI (−11.
20 to −0.
28) p=0.
04).
Treatment with atorvastatin (WMD −6.
83 mm3, 95% CI (−11.
68, to −1.
99) p=0.
006) showed a stronger regression than rosuvastatin (WMD −6.
41 mm3, 95% CI (−9.
43 to −3.
40) p<0.
0001).
At the end of follow-up, the LDL-C level on 80–100 mg/dl (WMD −8.
88 mm3, 95% CI (−12.
96 to −4.
81) p<0.
0001) reveal the strongest trend for plaque regression among all of the three LDL levels, including >80 mg/dl (−6.
01 mm3, 95% CI (−8.
82 to −3.
21) p<0.
0001), 80–100 mg/dl and <100 mg/dl (WMD −4.
22 mm3, 95% CI (−10.
27 to 1.
82) p=0.
017).
Plaque volume remained essentially unchanged in patients not treated with statins (WMD 0.
13 mm3, 95% CI (−4.
42 to 4.
68) p=0.
96).
Conclusions
statin therapy, particularly when achieving the LDL level on 80–100 mg/dl, appears to promote a significant regression of coronary plaque volume as measured by IVUS.
Related Results
GW24-e2475 Relationship between intravascular ultrasonic plaque morphology and quantitative acoustic densitometry of carotid plaque in patients with coronary artery disease
GW24-e2475 Relationship between intravascular ultrasonic plaque morphology and quantitative acoustic densitometry of carotid plaque in patients with coronary artery disease
Objectives
This study was designed to investigate the relationship between intravascular ultrasonic plaque morphology and quantitative acoustic densitometry by in...
Abstract P1-15-03: Assessing the association of statins with clinical outcomes in women with breast cancer
Abstract P1-15-03: Assessing the association of statins with clinical outcomes in women with breast cancer
Abstract
Background: A growing number of studies are claiming lipid-lowering medications (LLMs) primarily statins have anticancer properties to inhibit proliferation...
Atheroma Progression in Hyporesponders to Statin Therapy
Atheroma Progression in Hyporesponders to Statin Therapy
Objective—
Lowering low-density lipoprotein cholesterol (LDL-C) with statins has been demonstrated to slow plaque progression. This antiatherosclerotic effect in patien...
Predictors of statin adherence in primary care using real-world data
Predictors of statin adherence in primary care using real-world data
Abstract
Purpose
The objective of this study was to identify predictors of statin adherence in the primary and secondary preven...
1228-P: Comparison between Combination of Low- or Moderate-Intensity Statin with Ezetimibe and High-Intensity Statin Monotherapy for Primary Prevention of Cardiovascular Disease and All-Cause Mortalities in Patients with Type 2 Diabetes—A Propensity-Match
1228-P: Comparison between Combination of Low- or Moderate-Intensity Statin with Ezetimibe and High-Intensity Statin Monotherapy for Primary Prevention of Cardiovascular Disease and All-Cause Mortalities in Patients with Type 2 Diabetes—A Propensity-Match
Background and Aims: Here, we compared the effects of combination therapy of low- or moderate-statin with ezetimibe and high-intensity statin monotherapy in patients with type 2 di...
Abstract 213: Interleukins 17 a and 22: Are There Differences in Blood Concentrations of Patients With or Without Atherosclerosis ?
Abstract 213: Interleukins 17 a and 22: Are There Differences in Blood Concentrations of Patients With or Without Atherosclerosis ?
Introduction:
The role of the immune and inflammatory pathways in patients with atherosclerosis is important but not complete understood. The objective of this study wa...
Investigation of the Statin Paradox in Different Populations of VICs
Investigation of the Statin Paradox in Different Populations of VICs
Abstract
While numerous clinical studies have examined the effect of HMG-CoA reductase inhibitors (statin drugs) on calcific aortic valve disease (CAVD), their co...
Abstract 112: Statin Utilization in the Outpatient Clinic of a University Based Residency Training Program
Abstract 112: Statin Utilization in the Outpatient Clinic of a University Based Residency Training Program
Background:
Current guidelines released in 2013 recommend statins for five specific patient groups including persons with clinical atherosclerotic cardiovascular diseas...

